or Try an Advanced Search...

    Transplant Rejection Stocks List

    Symbol Grade Name % Change
    CDNA C CareDx, Inc. 4.85
    ALKS F Alkermes plc 0.80
    BMY F Bristol-Myers Squibb Company 0.66
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine

    Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

    Symbol Grade Name Weight
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 7.66
    MEDX F Horizon Kinetics Medical ETF 5.43
    PSIL F AdvisorShares Psychedelics ETF 4.75
    WBIY D WBI Power Factor High Dividend ETF 4.72
    IHE C iShares U.S. Pharmaceutical ETF 4.42
    View all Transplant Rejection ETFs...
    Compare ETFs
    Compare FTXH to IHE Compare FTXH to PSIL Compare WBIY to IHE

        Transplant Rejection Stocks Recent News

        Date Stock Title
        May 3 CDNA CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
        May 3 BMY Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
        May 3 BMY If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
        May 3 BMY The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
        May 3 BMY Bristol-Myers Squibb: A Lost Decade?
        May 2 BMY Schrodinger gets rights to cancer drug candidate back from Bristol
        May 2 ALKS Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
        May 2 BMY Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
        May 2 ALKS Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
        May 1 BMY Editas, Bristol Myers extend T cell therapy collaboration
        May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
        May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
        May 1 ALKS Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 ALKS Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
        May 1 BMY Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
        May 1 ALKS Alkermes Non-GAAP EPS of $0.43 misses by $0.15, revenue of $350.4M misses by $9.87M
        May 1 ALKS Alkermes plc Reports First Quarter 2024 Financial Results
        Apr 30 ALKS Alkermes Q1 2024 Earnings Preview
        Apr 30 BMY Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
        Apr 30 BMY J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine
        Transplant Rejection

        Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

        More about Transplant Rejection
        Browse All Tags